SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth potential.

The biopharmaceutical company announced that its President and CEO, Angelos Stergiou, will participate in several upcoming investor conferences, including the 2026 Stifel Virtual Targeted Oncology Forum, A.G.P.'s Annual Virtual Healthcare Conference, and TD Cowen's 7th Annual Oncology Innovation Summit. These events, scheduled to begin the following week, are expected to increase visibility and investor engagement with the late-stage clinical company.

Concurrently, SELLAS was featured in a market analysis as a high-growth tech stock, with the report noting the company's development of SLS009 (tambiciclib), a potential best-in-class CDK9 inhibitor. The analysis highlighted preclinical data showing the drug's increased efficacy against acute myeloid leukemia, particularly in treatment-resistant models, and forecasted strong revenue growth for the company, significantly outpacing the broader market average.